Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors is a phase 2, randomised interventional study registered as NCT07586813 by Peking University People's Hospital, with a registry enrolment figure of 220 participants, started 2025-12-22 and due to reach its primary completion in 2027-10-31. Interventions recorded: Romiplostim N01; All-trans retinoic acid. Conditions listed: Persistent Isolated Chemotherapy-Induced Thrombocytopenia; Chemotherapy-Induced Thrombocytopenia; Gastrointestinal Neoplasms; Pancreatic Cancer; Colorectal Cancer. Primary outcome: Overall Platelet Response Rate at Week 12. Pancreatic eligibility wording from the registry: "Prior diagnosis of a gastrointestinal/digestive system solid tumor, including but not limited to gastrointestinal tract, pancreatic, or colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.